This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhao, X.-Y. Articles by Dinter, H. Search for Related Content PubMed PubMed Citation Articles by Zhao, X.-Y. Articles by Dinter, H.

Targeting Tomoregulin for Radioimmunotherapy of Prostate Cancer

¹ Berlex Biosciences, Richmond, California; ² Nippon Medical School, Bunkyo-ku, Tokyo, Japan; and ³ Schering AG, Berlin, Germany

Requests for reprints: Xiao-Yan Zhao, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94806. Phone: 510-669-4347; Fax: 510-669-4220; E-mail: xiao-yan_zhao{at}berlex.com.

Radiotherapy is an effective approach for the treatment of local prostate cancer. However, once prostate cancer metastasizes, radiotherapy cannot be used due to the distribution of multiple metastases to lymph nodes and bones. In contrast, radioimmunotherapy should still be efficacious in metastatic prostate cancer as radioisotopes are brought to tumor cells by targeting antibodies. Here we identify and validate a prostate-expressed molecule, tomoregulin, as a target for radioimmunotherapy of prostate cancer. Tomoregulin is a transmembrane protein selectively expressed in the brain, prostate, and prostate cancer, but not expressed in other normal tissues. Immunohistochemical studies of tomoregulin protein in clinical samples show its location in the luminal epithelium of normal prostate, benign prostatic hyperplasia, and prostatic intraepithelial neoplasia. More importantly, the tomoregulin protein is expressed in primary prostate tumors and in their lymph node and bone metastases. The nature of tomoregulin as a transmembrane protein and its tissue-specific expression make tomoregulin an attractive target for radioimmunotherapy, in which tomoregulin-specific antibodies will deliver a radioisotope to prostate tumor cells and metastases. Indeed, biodistribution studies using a prostate tumor xenograft model showed that the ¹¹¹In-labeled anti-tomoregulin antibody 2H8 specifically recognizes tomoregulin protein in vivo, leading to a strong tumor-specific accumulation of the antibody. In efficacy studies, a single i.p. dose of 150 µCi (163 µg) ⁹⁰Y-labeled 2H8 substantially inhibits the growth rate of established LNCaP human prostate tumor xenograft in nude mice but produces no overt toxicity despite cross-reactivity of 2H8 with mouse tomoregulin. Our data clearly validate tomoregulin as a target for radioimmunotherapy of prostate cancer.

Key Words: Prostate cancer • radioimmunotherapy • LNCaP • tomoregulin • TMEFF2

This article has been cited by other articles:

				N. Ali and V. Knauper Phorbol Ester-induced Shedding of the Prostate Cancer Marker Transmembrane Protein with Epidermal Growth Factor and Two Follistatin Motifs 2 Is Mediated by the Disintegrin and Metalloproteinase-17 J. Biol. Chem., December 28, 2007; 282(52): 37378 - 37388. [Abstract] [Full Text] [PDF]

				P. M. Challita-Eid, K. Morrison, S. Etessami, Z. An, K. J. Morrison, J. J. Perez-Villar, A. B. Raitano, X.-C. Jia, J. M. Gudas, S. B. Kanner, et al. Monoclonal Antibodies to Six-Transmembrane Epithelial Antigen of the Prostate-1 Inhibit Intercellular Communication In vitro and Growth of Human Tumor Xenografts In vivo Cancer Res., June 15, 2007; 67(12): 5798 - 5805. [Abstract] [Full Text] [PDF]

				T. Heitner, N. Satozawa, K. Mclean, D. Vogel, R. R. Cobb, B. Liu, M. Mahmoudi, S. Finster, B. Larsen, Y. Zhu, et al. Obligate Multivalent Recognition of Cell Surface Tomoregulin following Selection from a Multivalent Phage Antibody Library J Biomol Screen, December 1, 2006; 11(8): 985 - 995. [Abstract] [PDF]

				R. Parry, D. Schneider, D. Hudson, D. Parkes, J.-A. Xuan, A. Newton, P. Toy, R. Lin, R. Harkins, B. Alicke, et al. Identification of a Novel Prostate Tumor Target, Mindin/RG-1, for Antibody-Based Radiotherapy of Prostate Cancer Cancer Res., September 15, 2005; 65(18): 8397 - 8405. [Abstract] [Full Text] [PDF]